Late-Stage Outcomes as Surrogates for Mortality in Cancer Screening Trials: A Systematic Review and Meta-analysis.

ABSTRACT: Late-stage cancer incidence has been proposed as a surrogate outcome for cancer-specific mortality in future screening trials. Two previous meta-analyses with 33 and 39 trials assessed trial-level surrogacy but provided inconsistent conclusions about the suitability of late-stage cancer endpoints replacing mortality. Our systematic review and meta-analysis (PROSPERO ID, CRD42023369320) investigated the association between the effect of cancer screening on the incidence of late-stage cancer and cancer-specific mortality. From 57 trials with 61 trial arm comparisons, correlation between late-stage incidence and mortality outcomes was 0.69 [95% confidence interval (CI), 0.47-0.84] for all cancers combined. Specifically, correlations were 0.58 (95% CI, 0.27-0.93) for bowel (N = 11 trials), 0.7

SUBMITTER: Rebolj M 

PROVIDER: S-EPMC12491949 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature